There is no consensus on the follow-up modalities in patients with head and neck cancer. This study aims to describe the pattern and survival outcomes of recurrences/second primary cancers in patients undergoing an intensive radiologic and clinical follow-up.
Study Design
Retrospective analysis.
Setting
Single academic tertiary care center.
Subjects and Methods
All patients with stage III-IV head and neck cancer treated with chemoradiotherapy at our institution between 1998 and 2010 were retrospectively reviewed. Persistent/recurrent disease within 6 months since the curative treatment and second primary cancers outside the upper aerodigestive tract were excluded. Data were analyzed by descriptive statistics. Surveillance was planned every 3 months in the first year, then with increasing intervals till the fifth year.
Results
A total of 326 patients were included. Out of all detected cancer recurrences (n = 106, 32%), 38 (36%) were locoregional, 44 (41%) were distant, and 24 (23%) were second primary cancers. Approximately 70% of recurrences were clinically and/or radiologically discovered, while 30% were diagnosed due to the patients’ symptoms. Of all clinically and/or radiologically discovered recurrences/second primary cancers (n = 74), 26 (35%) were curatively treated, with respect to 9 of the 32 (28%) diagnosed by symptoms. Median overall survival of recurrent curable cases did not significantly differ according to the detection modality (89 months by clinical/radiologic examination vs 85 by symptoms).
Conclusions
Clinical and radiologic follow-up identified more recurrences/second primary cancers than the symptom-driven monitoring, but the curability of cancer recurrence was similar regardless of detection modality. Prospective trials are needed to define the most effective follow-up strategy in head and neck cancer.
PignonJPle MaîtreAMaillardEBourhisJ; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14.
2.
BernierJCooperJSPajakTF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005;27:843-850.
3.
GrauJJCuchiATraserraJ, et al. Follow-up study in head and neck cancer: cure rate according to tumor location and stage. Oncology. 1997;54:38-42.
4.
CooneyTRPoulsenMG. Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer?Arch Otolaryngol Head Neck Surg. 1999;125:379-382.
5.
BoysenMLovdalOTausjoJWintherF. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer. 1992;28:426-430.
6.
de VisscherAVManniJJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity: does it make sense?Arch Otolaryngol Head Neck Surg. 1994;120:934-939.
7.
SturgisEMMillerRH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol. 1995;104:946-954.
8.
RitoeSCKrabbePFKaandersJHvan den HoogenFJVerbeekALMarresHA. Value of routine follow-up for patients cured of laryngeal carcinoma. Cancer. 2004;101:1382-1389.
9.
MeregagliaMCairnsJLicitraLBossiP. The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: an economic evaluation. Eur J Cancer. 2018;93:89-98.
10.
FurmanMJLambertLASullivanMEWhalenGF. Rational follow-up after curative cancer resection. J Clin Oncol. 2013;31:1130-1133.
11.
BoekhoutAHMaunsellEPondGR, et al; FUPII Trial Investigators. A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial. J Cancer Surviv. 2015;9:683-691.
12.
BenamoreRShepherdFALeighlN, et al. Does intensive follow-up alter outcome in patients with advanced lung cancer?J Thorac Oncol. 2007;2:273-281.
13.
RojasMPTelaroERussoA, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;(1):CD001768. Update in: Cochrane Database Syst Rev. 2016;(5):CD001768.
14.
HuntingtonSFSvobodaJDoshiJA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33:1467-1474.
15.
ThompsonCAGhesquieresHMaurerMJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32:3506-3512.
16.
KostakogluLFardaneshRPosnerM, et al. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist. 2013;18:1108-1117.
17.
JungYHSongCMParkJH, et al. Efficacy of current regular follow-up policy after treatment for head and neck cancer: need for individualized and obligatory follow-up strategy. Head Neck. 2014;36:715-721.
18.
PfisterDGSpencerSBrizelDM. Head and neck cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13:847-855.
19.
SimoRHomerJClarkeP. Follow-up after treatment for head and neck cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130:S208-S211.
20.
PerroneFGloghiniACortelazziBBossiPLicitraLPilottiS. Isolating p16 positive/HPV-negative oropharyngeal cancer: an effort worth making. Am J Surg Pathol. 2011;35:774-777.
21.
PerroneFSuardiSPastoreE, et al. Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma [erratum in Clin Cancer Res. 2007;13:4313]. Clin Cancer Res. 2006;12:6643-6651.
22.
SchnipperLESmithTJRaghavanD, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30:1715-1724.
23.
SchwartzDLBarkerJJrChanskyK, et al. Postradiotherapy surveillance practice for head and neck squamous cell carcinoma—too much for too little?Head Neck. 2009;25:990-999.
24.
KissunDMagennisPLoweDBrownJSVaughanEDRogersSN. Timing and presentation of recurrent oral and oropharyngeal squamous cell carcinoma and awareness in the outpatient clinic. Br J Oral Maxillofac Surg. 2006;44:371-376.
25.
FlynnCJKhaouamNGardnerS, et al. The value of periodic follow-up in the detection of recurrences after radical treatment in locally advanced head and neck cancer. Clin Oncol (R Coll Radiol). 2010;22:868-873.
26.
ManikantanKKhodeSDwivediRC, et al. Making sense of post-treatment surveillance in head and neck cancer: when and what of follow-up. Cancer Treat Rev. 2009;35:744-753.
27.
JoshiACalmanFO’ConnellMJeannonJPPracyPSimoR. Current trends in the follow-up of head and neck cancer patients in the UK. Clin Oncol (R Coll Radiol). 2010;22:114-118.
28.
PanielloRCVirgoKSJohnsonMHClementeMFJohnsonFE. Practice, patterns and clinical guidelines for post-treatment follow-up of head and neck cancers: a comparison of 2 professional societies. Arch Otolaryngol Head Neck Surg. 1999;125:b309b-b313.
29.
BrocksteinBHarafDJRademakerAW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179-1186.
30.
MorrisLGTSikoraAGHayesRBPatelSGGanlyI. Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Cancer Causes Control. 2011;22:671-679.
31.
BourhisJLe MaitreABaujatBAudryHPignonJP; Meta-analysis of Chemotherapy in Head, Neck Cancer Collaborative Group; Meta-analysis of Radiotherapy in Carcinoma of Head, Neck Collaborative Group; Meta-analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group. Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol. 2007;19:188-194.
32.
BernierJDomengeCOzsahinM, et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
33.
ForastiereAAGoepfertHMaorM, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091-2098.
34.
FakhryCZhangQNguyen-TanPF, et al. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32:3365-3373.
35.
ArgirisALiSGhebremichaelM. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol. 2014;25:1410-1416.
36.
Na’araSAmitMBillanSCohenJTGilZ. Outcome of patients undergoing salvage surgery for recurrent nasopharyngeal carcinoma: a meta-analysis. Ann Surg Oncol. 2014;21:3056-3062.
37.
WarrenJLMariottoABMeekinsAToporMBrownML. Current and future utilization of services from medical oncologists. J Clin Oncol. 2008;26:3242-3247.
38.
BrennerDJHallEJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-2284.
39.
ThompsonCACharlsonMESchenkeinE. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol. 2010;21:2262-2266.
40.
MeregagliaMCairnsJAlfieriS, et al. Eliciting preferences for clinical follow-up in patients with head and neck cancer using best-worst scaling. Value Health. 2017;20:799-808.
41.
ClinicalTrials.gov. Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer (HETeCo). https://clinicaltrials.gov/ct2/show/NCT02262221. Accessed April 23, 2019.
